CAMBRIDGE, Mass., Sept. 1,
2022 /PRNewswire/ -- Akebia Therapeutics,
Inc. (Nasdaq: AKBA), a biopharmaceutical company with the
purpose to better the lives of people impacted by kidney disease,
today announced that John Butler,
Chief Executive Officer, will present virtually at the H.C.
Wainwright 24th Annual Global Investment Conference. The
hybrid conference will take place September 12–14, 2022.
The presentation will be available on-demand beginning
September 12, 2022 through the
Investors section of Akebia's website at
https://ir.akebia.com for approximately 90 days.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is
a fully integrated biopharmaceutical company with the purpose to
better the lives of people impacted by kidney disease. Akebia was
founded in 2007 and is headquartered in Cambridge, Massachusetts. For more
information, please visit our website at www.akebia.com, which does
not form a part of this release.
Akebia Therapeutics Contact
View original content to download
SOURCE Akebia Therapeutics